Home › SEC Filings › Press Releases
Press Releases
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| RYTM | PRESS-RELEASE | bullish | 6/10 | Rhythm Pharmaceuticals announced that the Phase 3 TRANSCEND trial results for setmelanotide (IMCIVREE) in acquired hypot | Jul 8, 2026 |
| PHGE | PRESS-RELEASE | neutral | 4/10 | BiomX announced a non-binding LOI to acquire 60% of Tsoock Defense Technologies for $10.4M, payable mostly in quarterly | Jul 8, 2026 |
| OKYO | PRESS-RELEASE | bullish | 6/10 | OKYO Pharma announced positive FDA Type D meeting feedback validating a single-dose Phase 3 pivotal trial design for urc | Jul 8, 2026 |
| CATX | PRESS-RELEASE | neutral | 2/10 | Perspective Therapeutics announced the appointment of Paul Lyne, Ph.D., as Chief Science Officer, succeeding co-founder | Jul 8, 2026 |
| MSLE | PRESS-RELEASE | bullish | 7/10 | Satellos reported six-month interim data from the TRAILHEAD Phase 2 study of SAT-3247 in adults with Duchenne muscular d | Jul 8, 2026 |
| LYB | PRESS-RELEASE | neutral | 2/10 | LyondellBasell announced a collaboration with Mondelez, Amcor, and Taghleef to produce flexible packaging for Marabou ch | Jul 7, 2026 |
| AXSM | PRESS-RELEASE | neutral | 4/10 | Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, a 468-pati | Jul 7, 2026 |
| AGIO | PRESS-RELEASE | bullish | 7/10 | Agios announced FDA Priority Review acceptance of its sNDA for mitapivat in sickle cell disease, with a PDUFA goal date | Jul 7, 2026 |
| WST | PRESS-RELEASE | neutral | 1/10 | West Pharmaceutical Services, Inc. announced it will host a conference call on July 23, 2026 to discuss its Q2 2026 resu | Jul 7, 2026 |
| DBVT | PRESS-RELEASE | neutral | 2/10 | DBV Technologies published its semi-annual liquidity contract report with ODDO BHF, detailing share buyback and sales ac | Jul 6, 2026 |
| PBH | PRESS-RELEASE | mixed | 5/10 | Prestige closed its $150M acquisition of LaCorium Health, priced a $400M 6.25% senior notes offering to refinance its 5. | Jul 6, 2026 |
| LYB | PRESS-RELEASE | neutral | 1/10 | LyondellBasell announced it will report its Q2 results on July 31, 2026. | Jul 6, 2026 |
| PHVS | PRESS-RELEASE | bullish | 6/10 | Pharvaris announced FDA acceptance of its New Drug Application (NDA) for deucrictibant immediate-release capsules for on | Jul 6, 2026 |
| IMRN | PRESS-RELEASE | bullish | 6/10 | Immuron engaged Pullan Consulting to secure a strategic partner for its IMM-529 program targeting C. difficile infection | Jul 6, 2026 |
| ATAI | PRESS-RELEASE | neutral | 4/10 | AtaiBeckley announced completion of enrollment (156 patients) in the Phase 2b Elumina trial of VLS-01 for treatment-resi | Jul 6, 2026 |
| MOLN | PRESS-RELEASE | neutral | 3/10 | Molecular Partners provided a pipeline update for its Radio-DARPin therapeutics, confirming ongoing Phase 1/2a dosing fo | Jul 6, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech disclosed that a major shareholder, Celtic Lux Holdings (formerly Alvogen Lux Holdings), has pledged 88,940,619 | Jul 3, 2026 |
| XENE | PRESS-RELEASE | neutral | 1/10 | Xenon Pharmaceuticals granted 20,200 stock options and 11,850 RSUs to four new non-officer employees as inducement equit | Jul 2, 2026 |
| MGNX | PRESS-RELEASE | bullish | 6/10 | MacroGenics completed the sale of its GMP manufacturing operations to Bora Pharmaceuticals for $122.5 million, transitio | Jul 2, 2026 |
| RVMD | PRESS-RELEASE | bullish | 7/10 | Revolution Medicines reported positive Phase 1/2 data for zoldonrasib in RAS G12D metastatic pancreatic cancer at ESMO G | Jul 2, 2026 |
| VRXA | PRESS-RELEASE | neutral | 3/10 | VERAXA Biotech announced the initiation of cell line development for its lead BiTAC-TCE program with ATUM, a critical bu | Jul 2, 2026 |
| TENX | PRESS-RELEASE | neutral | 7/10 | Tenax Therapeutics announced that Phase 3 LEVEL trial results for TNX-103 (oral levosimendan) in PH-HFpEF will be presen | Jul 2, 2026 |
| MOLN | PRESS-RELEASE | neutral | 4/10 | Molecular Partners announced first patient dosing in the US Phase 1/2a study of MP0712, a DLL3-targeting 212Pb-labeled R | Jul 2, 2026 |
| TLX | PRESS-RELEASE | bullish | 7/10 | Telix announced FDA alignment to proceed to Part 2 of the ProstACT Global Phase 3 trial for TLX591-Tx in metastatic cast | Jul 1, 2026 |
| SNDX | PRESS-RELEASE | neutral | 2/10 | Syndax granted 250,700 performance-based stock options to 8 new hires under its 2023 Inducement Plan, with four-year gra | Jul 1, 2026 |
| ABVX | PRESS-RELEASE | bearish | 6/10 | Abivax priced an upsized $800M public offering of 6.4M ADSs at $125 per ADS, a 2.4% premium to VWAP, representing 8% dil | Jul 1, 2026 |
| CELZ | PRESS-RELEASE | neutral | 3/10 | Creative Medical Technology Holdings issued a mid-year CEO update highlighting clinical progress across its Olastrocel ( | Jul 1, 2026 |
| EVAX | PRESS-RELEASE | neutral | 3/10 | Evaxion announced a poster presentation at the International Herpesvirus Workshop 2026 for its preclinical CMV vaccine c | Jul 1, 2026 |
| SXTP | PRESS-RELEASE | neutral | 4/10 | 60 Degrees Pharmaceuticals announced that the independent Data Safety Monitoring Board recommended continuation of its B | Jul 1, 2026 |
| ALVO | PRESS-RELEASE | neutral | 4/10 | Alvotech secured an additional $75 million term loan from GoldenTree Asset Management at 12.5% interest, maturing Decemb | Jul 1, 2026 |